Model List of Essential Medicines

Allopurinol

Section	Indications
Supportive medicines Parenteral > General injections > IV: 500 mg (as sodium) powder for injection Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Darbepoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin alfa

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Epoetin beta

Section	Indications
Supportive medicines	Therapeutic equivalent to erythropoiesis-stimulating agents for Drug-induced aplastic anaemia

Erythropoiesis-stimulating agents

Section	Indications
Supportive medicines Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)	Drug-induced aplastic anaemia

Mesna

Section	Indications
Supportive medicines Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule Oral > Solid: 400 mg; 600 mg Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule Oral > Solid > tablet: 400 mg; 600 mg Oral > Other: 600 mg Oral > Solid > tablet: 400 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of other specified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Germ cell tumour of testis

Rasburicase

Section	Indications
Supportive medicines Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution	Tumour lysis syndrome

Zoledronic acid

Section	Indications
Supportive medicines Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow